Application No.: 10/590,733 Docket No.: 3587-0126PUS1
Reply to Office Action of April 28, 2010 Page 2 of 5

REMARKS

Applicants thank the Examiner for the thorough examination given the present application.

Status of the Claims

Claims 1-3, 5-22, 24-31, and 33-45 are pending in the above-identified application. Claims 20-22, 24-31, and 33-42 are currently withdrawn from consideration. As such, claims 1-3, 5-19, and 43-45 stand ready for further action on the merits. In view of the following remarks, Applicants respectfully request that the Examiner withdraw all rejections and allow the currently pending claims.

Issues over the Cited References

- 1) Claims 1, 5-6, 9-11, and 14 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Sessoms et al. '070 (US 3,851,070) in view of Melnick '830 (US 3,216,830) and Rudan et al. '754 (US 5,366,754).
- 2) Claims 2-3 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Sessoms et al. '070, Melnick '830, and Rudan et al. '754 in view of Unnithan '261 (US 5,932,261).
- 3) Claims 12-13 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Sessoms et al. '070, Melnick '830, and Rudan et al. '754 in view of McGee.
- 4) Claims 7-8 and 17-19 are rejected under 35 U.S.C. § 103(a) as being obvious over Sessoms et al. '070, Melnick '830, and Rudan et al. '754 in view of Ashmead et al. '427 (US 4,725,427).
- 5) Claims 15-16 and 43-45 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Sessoms et al. '070 in view of Melnick '830, Rudan et al. '754, and Unnithan '261 in view of McGee.

Applicants respectfully traverse. Reconsideration and withdrawal of these rejections are respectfully requested based on the following considerations.

Application No.: 10/590,733 Docket No.: 3587-0126PUS1
Reply to Office Action of April 28, 2010 Page 3 of 5

Legal Standard for Determining Prima Facie Obviousness

MPEP 2141 sets forth the guidelines in determining obviousness. First, the Examiner has to take into account the factual inquiries set forth in *Graham v. John Deere*, 383 U.S. 1, 17, 148 USPQ 459, 467 (1966), which has provided the controlling framework for an obviousness analysis. The four *Graham* factors are:

- (a) determining the scope and content of the prior art;
- (b) ascertaining the differences between the prior art and the claims in issue;
- (c) resolving the level of ordinary skill in the pertinent art; and
- (d) evaluating any evidence of secondary considerations.

Graham v. John Deere, 383 U.S. 1, 17, 148 USPQ 459, 467 (1966).

Second, the Examiner has to provide some rationale for determining obviousness. MPEP 2143 sets forth some rationales that were established in the recent decision of *KSR International Co. v Teleflex Inc.*, 82 USPQ2d 1385 (U.S. 2007).

As the MPEP directs, all claim limitations must be considered in view of the cited prior art in order to establish a *prima facie* case of obviousness. *See* MPEP 2143.03.

Distinctions over the Cited References

The Examiner asserts that Sessoms et al. '070 disclose soy protein in the range of 20-35% (col. 3, lines 5-8). As the Examiner admits, Sessoms et al. '070 fail to disclose the content range of the soy flour of the present invention. As such, the Examiner relies on Rudan et al. '754 to disclose the claimed range of the soy flour. However, the range in Rudan et al. '754 is for peanut flour rather than soy flour. One of ordinary skill in the art would not consider peanut flour and soy flour to be interchangeable.

Specifically, as evidenced by the enclosed articles, one of ordinary skill in the art would not turn to a disclosure regarding peanut flour instead of soy flour. A formulation with peanut flour has a risk because of allergies to peanut products. The potentially fatal risk of peanut allergy exists in a much greater percent of the population than a soy allergy. The enclosed Sicherer et al. article notes that peanut allergies are more prevalent and more severe than soy allergies. Furthermore, a peanut allergy is usually permanent, but a soy allergy is transient. Figures 1 and 2 of the enclosed Cordle article also support these findings. As such, one of ordinary skill in the art would not combine Sessoms et al. '070 with Rudan et al. '754.

Application No.: 10/590,733 Docket No.: 3587-0126PUS1 Page 4 of 5

Reply to Office Action of April 28, 2010

In addition, the specific percentage of protein, fats, carbohydrates, and antioxidants in the

food product of the present invention is unique. One of ordinary skill in the art would have no reason, rationale, or motivation to arrive at the specific percentages of the present invention.

Applicants contend that the Examiner has indulged in impermissible hindsight in making the

obviousness rejections. That is, the outstanding Office Action merely reflects the piecewise

combination of various elements of various patents, which directly contradicts the rationale of

MPEP 2143.01 that the "fact that the claimed invention is within the capabilities of one of

ordinary skill in the art is not sufficient by itself to establish *prima facie* obviousness."

In view of the above, the cited references or the knowledge in the art provide no reason or

rationale that would allow one of ordinary skill in the art to arrive at the present invention as

claimed. Therefore, a prima facie case of obviousness has not been established, and withdrawal

of the outstanding rejections is respectfully requested. Any contentions of the USPTO to the

contrary must be reconsidered at present.

Conclusion

All of the stated grounds of rejection have been properly traversed, accommodated, or

rendered moot. Applicants therefore respectfully request that the Examiner reconsider all

presently outstanding rejections and that they be withdrawn. It is believed that a full and

complete response has been made to the outstanding Office Action, and as such, the present

application is in condition for allowance.

Should there be any outstanding matters that need to be resolved in the present

application, the Examiner is respectfully requested to contact Chad M. Rink, Registration No.

58,258, at the telephone number of the undersigned below to conduct an interview in an effort to

expedite prosecution in connection with the present application.

BIRCH, STEWART, KOLASCH & BIRCH, LLP

PCL/CMR/cmr

Application No.: 10/590,733 Docket No.: 3587-0126PUS1

Reply to Office Action of April 28, 2010

Page 5 of 5

If necessary, the Director is hereby authorized in this, concurrent, and future replies to charge any fees required during the pendency of the above-identified application or credit any overpayment to Deposit Account No. 02-2448.

Dated: SEP 2 8 2010

Respectfully submitted,

Paul C. Lewis

Registration No.: 43,368

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road, Suite 100 East

P.O. Box 747

Falls Church, VA 22040-0747

703-205-8000

Attachments: Cordle, "Soy Protein Allergy: Incidence and Relative Severity," *Fifth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease* (2004), pages 1213S-1219S;

Jemmali, "Collaborative Studies on the Determination of Aflatoxins in Peanut Products in France," *INRA*, pages 267-270); and

Sicherer et al., "Peanut and soy allergy: a clinical and therapeutic dilemma," *Allergy* (2000), pages 515-521.